Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
32 participants
INTERVENTIONAL
2021-05-26
2022-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of a Longevity Supplement on Aging and Photoaging
NCT05262036
Safety & Efficacy of Extended Longevity Protocol
NCT05296993
Greens-Based Crossover Trial to Improve Epigenetic Aging in Adults
NCT06537232
A Dietary Supplement Examined for Anti-ageing Effects
NCT06714162
To Evaluate the Efficacy and Safety of NMN as an Anti-ageing Supplement in Middle Aged and Older (40-65 Years) Adults
NCT04823260
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AC-11
6 months of treatment with AC-11
AC-11
6-months of treatment with AC-11
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AC-11
6-months of treatment with AC-11
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age Range 55 years and older
3. The patient must be able to comply with the treatment plan and laboratory tests
Exclusion Criteria
2. No immune system issues or immunodeficiency disease
3. No history of viral illness which could be reactivated by immune downregulation
4. Presence of clinically significant acute or unstable cardiovascular and cerebrovascular (stroke)
5. Diagnosis of a transient ischemic attack in the 6 months prior to screening
6. Patients infected with hepatitis C or HIV
7. Patients with Body Mass Index (BMI) \> 40 kg/m2
8. Presence of active infection
9. Any other illness, psychiatric disorder, alcohol or chemical dependence that in the opinion of the investigator would render a patient unsuitable to participate in the study
10. Unable or unwilling to provide a required blood sample for testing
11. As for the male-participants they are recommended to avoid fertilization for the first 6 months after the clinical trial.
12. If the patient has previously used AM/PM HealthSpan system supplements at any time before the start of the trial.
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Optigenex, Inc
UNKNOWN
TruDiagnostic
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Phillip Gallegos
Role: PRINCIPAL_INVESTIGATOR
Thrive Medicine Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Thrive Medicine Clinic
Sugar Land, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Guthrie OW, Xu H. Reduced Phosphorylation of Histone Variant H2Ax in the Organ Of Corti Is Associated With Otoprotection from Noise Injury. Otolaryngology 2013; 3:131.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OI-AC11-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.